Repeated injection of PEGylated solid lipid nanoparticles induces accelerated blood clearance in mice and beagles

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2891-2900

  Zhao, Yongxue ^a   Wang, Long ^a   Yan, Mina ^a   Ma, Yanling ^a   Zang, Guangxi ^a   She, Zhennan ^a   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

ABC phenomenon; Circulation time; Polyethylene glycol; SLNs

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; PEGYLATED SOLID LIPID NANOPARTICLE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR CHANGE; CHEMICAL COMPOSITION; CIRCULATION TIME; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENCAPSULATION; HALF LIFE TIME; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; REACTION TIME; ZETA POTENTIAL;

ANIMALS; AREA UNDER CURVE; DOGS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; NANOPARTICLES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SPLEEN; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

EID: 84870361841     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S30943     Document Type: Article

References (39)

1. Nie S. Understanding and overcoming major barriers in cancer nanomedicine. Nanomedicine (Lond). 2010;5(4):523-528.
2. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev. 1995;17(1):31-48.
3. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta. 1991; 1066(1):29-36.
4. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta. 1992;1113(2):171-199.
5. Stolnik S, Illum L, Davis SS. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev. 1995;16(2-3):195-214.
6. Laverman P, Carstens MG, Boerman OC, etal. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther. 2001;298(2):607-612.
7. Dams ET, Laverman P, Oyen WJ, etal. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther. 2000;292(3):1071-1079.
8. Ishihara T, Takeda M, Sakamoto H, etal. Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res. 2009;26(10):2270-2279.
9. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated PEGylated nanoparticle. J Control Release. 2007;118(1):38-53.
10. Koide H, Asai T, Hatanaka K, etal. Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm. 2008;362(1-2): 197-200.
11. Tagami T, Nakamura K, Shimizu T, Ishida T, Kiwada H. Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release. 2009;137(3):234-240.
12. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release. 2011; 151(2):149-154.
13. Kaminskas LM, McLeod VM, Porter CJ, Boyd BJ. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. J Pharm Sci. 2011;100(11):5069-5077.
14. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161-177.
15. Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev. 2007;59(6):491-504.
16. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999;59(3): 299-307.
17. Parveen S, Misra R, Sahoo SK. Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging. Nanomedicine. 2012;8(2): 147-166.
18. Wong HL, Bendayan R, Rauth AM, Wu XY. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J Pharm Sci. 2004;93(8):1993-2008.
19. Kang KW, Chun MK, Kim O, etal. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine. 2010;6(2):210-213.
20. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther. 2006;317(3):1372-1381.
21. Zhang XG, Miao J, Dai YQ, Du YZ, Yuan H, Hu FQ. Reversal activity of nanostructured lipid carriers loading cytotoxic drug in multi-drug resistant cancer cells. Int J Pharm. 2008;361(1-2):239-244.
22. Wong HL, Rauth AM, Bendayan R, etal. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res. 2006;23(7): 1574-1585.
23. Ishida T, Ichihara M, Wang X, etal. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release. 2006; 112(1):15-25.
24. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release. 2007;122(3):349-355.
25. Koide H, Asai T, Hatanaka K, etal. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm. 2010;392(1-2):218-223.
26. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release. 2007;119(2):236-244.
27. Ishida T, Ichikawa T, Ichihara M, Sadzuka Y, Kiwada H. Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release. 2004;95(3):403-412.
28. Ishida T, Atobe K, Wang X, Kiwada H. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release. 2006; 115(3):251-258.
29. Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005;105(3):305-317.
30. Sroda K, Rydlewski J, Langner M, Kozubek A, Grzybek M, Sikorski AF. Repeated injections of PEG-PE liposomes generate anti-PEG antibodies. Cell Mol Biol Lett. 2005;10(1):37-47.
31. Shimada K, Matsuo S, Sadzuka Y, etal. Determination of incorporated amounts of poly(ethylene glycol)-derivatized lipids in liposomes for the physicochemical characterization of stealth liposomes. Int J Pharm. 2000;203(1-2):255-263.
32. Sadzuka Y, Nakade A, Tsuruda T, Sonobe T. Study on the characterization of mixed polyethyleneglycol modified liposomes containing doxorubicin. J Control Release. 2003;91(3):271-280.
33. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev. 2009;61(6):428-437.
34. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-515.
35. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan: DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med. 1999;5(4):387-391.
36. Dos Santos N, Allen C, Doppen AM, etal. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta. 2007;1768(6):1367-1377.
37. Humphrey JH. Tolerogenic or immunogenic activity of hapten-conjugated polysaccharides correlated with cellular localization. Eur J Immunol. 1981;11(3):212-220.
38. Mond JJ, Vos Q, Lees A, Snapper CM. T cell independent antigens. Curr Opin Immunol. 1995;7(3):349-354.
39. Basten A, Silveira PA. B-cell tolerance: mechanisms and implications. Curr Opin Immunol. 2010;22(5):566-574.